Highest-materiality recent filing
Kyntra Bio reports Q1 2026 net loss of $15.1M ($3.74/share) and cash runway into 2028
Phase 2 trial of FG-3246 in mCRPC enrolling; interim analysis expected in 4Q 2026.
Kyntra Bio receives Nasdaq delisting notice for failing $50M assets/revenue rule
Received Nasdaq letter on April 2, 2026, for non-compliance with Listing Rule 5450(b)(3)(A) regarding $50M total assets and revenue.
Kyntra Bio reports FY2025 revenue $6.4M, net loss $58.2M; cash $109.4M into 2028
Full yr 2025 revenue from cont ops $6.4M (vs $29.6M in 2024); net loss $58.2M (vs $153.1M).
FibroGen rebrands as Kyntra Bio; new ticker KYNB effective Jan 8; pipeline milestones detailed
Name changed to Kyntra Bio, Inc. via Certificate of Amendment effective 4:30pm ET Jan 7, 2026.
FibroGen Q3 2025: Net loss $13.1M, China sale ~$220M, cash $121.1M into 2028
Net loss from continuing ops $13.1M ($3.25 loss per share) vs $48.3M ($12.01 loss) YoY.
FibroGen completes sale of China business to AstraZeneca for ~$220M; repays $81M term loan
Sale price ~$220M: $85M enterprise value plus ~$135M net cash held in China.
FibroGen completes $220M sale of China ops to AstraZeneca; cash runway extended to 2028
Total consideration ~$220M ($85M enterprise value + ~$135M net cash), $60M above initial guidance.
China State Administration for Market Regulation decided not to prohibit AstraZeneca's acquisition of FibroGen China.
FibroGen Q2 loss narrows to $13.7M; China sale to AstraZeneca now ~$210M, cash runway into 2028
Net loss from continuing ops $13.7M ($3.38/sh) vs $47.1M loss ($11.79/sh) in Q2 2024; revenue $1.3M.
FibroGen terminates prior HiFiBiO license deal, licenses anti-CCR8 and anti-Gal-9 assets
Terminated Exclusive License and Option Agreement with HiFiBiO dated June 2021, as amended Feb 2024.
FibroGen to effect 1-for-25 reverse stock split to regain Nasdaq compliance
Reverse split effective 5:00 p.m. ET June 16, 2025; post-split trading begins June 17.
FibroGen shareholders approve reverse stock split; appoints Michael Kauffman to board
Shareholders approved reverse stock split (1:10-1:25) to meet Nasdaq listing requirement; 85% voted in favor.
FibroGen Q1 net loss narrows to $16.8M; China sale consideration raised to ~$185M
Total revenue from continuing ops fell to $2.7M from $25.4M YoY; net loss improved to $16.8M ($0.16/sh) from $49.0M.
FibroGen publishes Phase 1 FG-3246 mCRPC data in JCO; ORR 20%, DCR 80%, mid-2025 Phase 2 start
Phase 1 study of FG-3246 (anti-CD46 ADC) in mCRPC published in Journal of Clinical Oncology.
FibroGen gets Nasdaq delisting notice; appeals; reports Q4 loss of $8.7M, China sale to AstraZeneca
Nasdaq notified FibroGen on March 12, 2025 that it failed to regain $1.00 minimum bid price; delisting stayed after March 14 appeal; hearing pending.
FibroGen enters ATM equity offering agreement for up to $30M with BofA Securities
May sell up to $30M of common stock from time to time through BofA as sales agent.
FibroGen sells China ops to AstraZeneca for ~$160M; cash runway to 2027
Purchase price: $85M enterprise value plus net China cash (~$75M) for total ~$160M.
FibroGen Q3 revenue up 15% to $46.3M; net loss narrows to $17.1M; reiterates FY guidance
Net product revenue from roxadustat in China $46.2M, +57% YoY; total roxadustat net sales $96.6M, +25% YoY.
FibroGen terminates headquarters lease, accelerates expiration to Dec 31, 2024, with $10M settlement
Entered Lease Termination Agreement with landlord ARE-San Francisco No.43 Owner, LLC.
FibroGen receives Nasdaq delisting notice over bid price below $1.00
Nasdaq notified FibroGen on Sept 12 that its stock closed below $1.00 for 30 consecutive days, triggering potential delisting.
FibroGen terminates CFO Juan Graham and CMO Deyaa Adib as part of cost reduction plan
CFO Juan Graham and CMO Deyaa Adib given termination notice on Aug 30, 2024.
FibroGen cuts 75% of U.S. workforce (127 employees); charges $16-18M
Workforce reduction of ~75% (127 U.S. employees) effective Aug 2, 2024.
FibroGen Q2 net revenue +14% to $50.6M; cuts US workforce 75% after pancreatic trial failures
Net loss narrowed to $15.5M ($0.16/sh) from $87.7M ($0.90) YoY; revenue $50.6M (+14%).
FibroGen Q1 2024 revenue up 55% YoY to $55.9M; net loss narrows to $32.9M
Net loss of $32.9M ($0.33 per share) vs $76.7M loss ($0.81 per share) in Q1 2023.
FibroGen FY23 rev $147.8M (+5% YoY), net loss $284.2M; guides China roxadustat $300-340M
Full year 2023 total revenue $147.8M, up 5% YoY; net loss $284.2M ($2.92 per share), narrower than $293.7M loss in 2022.
FibroGen Q3 revenue up 155% to $40.1M; roxadustat China sales up 31%
Net loss of $63.6M ($0.65 loss per share) vs $91.7M ($0.98) YoY; restructuring charge of $12.6M.
FibroGen receives Nasdaq notice of non-compliance for bid price below $1.00
Closing bid price of FGEN stock below $1.00 for 30 consecutive business days as of Oct 24, 2023.
FibroGen CMO Mark Eisner resigns; search underway for replacement
CMO Mark Eisner resigns effective Sept 8, 2023; departure voluntary with no disagreement.
FibroGen Phase 3 pamrevlumab trial for DMD fails to meet primary endpoint
Primary endpoint (NSAA total score change at week 52) not met: mean difference -0.528 points (p=0.5553).
FibroGen Q2 revenue up 49% but net loss widens; multiple Phase 3 failures; new CEO appointed
Q2 total revenue $44.3M (+49% YoY); net loss $87.7M ($0.90) vs $72.6M ($0.78) last year; includes $24.6M one-time charge.
FibroGen cuts US workforce 32% (104 employees); expects $13-15M charges
Workforce reduction of ~32% (104 U.S. employees) approved July 14, 2023.
FibroGen Phase 3 ZEPHYRUS-1 trial of pamrevlumab for IPF fails primary endpoint
Phase 3 ZEPHYRUS-1 did not meet primary endpoint: change in FVC at week 48 (p=0.29); placebo-corrected difference 70 ml.
FibroGen's pamrevlumab fails Phase 3 DMD study in non-ambulatory patients; primary endpoint not met
Phase 3 LELANTOS-1 study of pamrevlumab in non-ambulatory DMD patients did not meet primary endpoint (PUL 2.0 score at week 52).
FibroGen announces positive Phase 3 results for roxadustat in chemotherapy-induced anemia in China
Met primary endpoint: noninferiority to erythropoietin alfa in hemoglobin change from baseline to average weeks 9-13.
FibroGen Q1 loss $0.81; China roxadustat sales up 47%; pamrevlumab Ph3 data expected in 2023
Net loss $76.7M ($0.81/sh) vs $63.2M ($0.68/sh) in Q1 2022.
FibroGen enters $75M senior secured term loan with Morgan Stanley Tactical Value; up to $150M total
Initial $75M term loan funded by May 8, 2023; additional $37.5M milestone-based loan and $37.5M discretionary loan available.
On June 4, 2025, Aoife Brennan, M.B., B.Ch. provided to the Board of Directors (the “Board”) notification of her resignation from the Board of FibroGen, effective June 4, 2025.
Effective June 4, 2025, the Board of the Company, upon recommendation of the Nominating and Corporate Governance Committee, appointed Michael Kauffman, M.D., Ph.D. as a Class III director of the Company.
Upon the closing of the sale of FibroGen International pursuant to the Share Purchase Agreement, Christine L. Chung, who currently serves as our Senior Vice President, China Operations, will cease employment with us.
On September 12, 2024, Suzanne Blaug, Benjamin Cravatt, and Gerald Lema each provided to the Board of Directors (the “Board”) notification of their resignations from the Board of FibroGen, Inc. (the “Company”), effective September 30, 2024.
On September 12, 2024, Suzanne Blaug, Benjamin Cravatt, and Gerald Lema each provided to the Board of Directors (the “Board”) notification of their resignations from the Board of FibroGen, Inc. (the “Company”), effective September 30, 2024.
On September 12, 2024, Suzanne Blaug, Benjamin Cravatt, and Gerald Lema each provided to the Board of Directors (the “Board”) notification of their resignations from the Board of FibroGen, Inc. (the “Company”), effective September 30, 2024.
the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.
the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.
On October 2, 2023, the Board of Directors (the “Board”) of FibroGen, Inc. (the “Company”) appointed Interim Chief Executive Officer Thane Wettig as (i) Chief Executive Officer and (ii) a member of the Board.
On August 31, 2023, Mark Eisner, M.D. resigned from his position as Chief Medical Officer of FibroGen, Inc. (the "Company"), effective September 8, 2023, to pursue other opportunities.
He succeeds Enrique Conterno, who has resigned as Chief Executive Officer and from the Board, and who will remain with the Company as Special Advisor to the Interim CEO through August 8, 2023.
the Board of Directors (the "Board") has appointed Thane Wettig, age 58, to the position of Interim Chief Executive Officer (“Interim CEO”), effective July 23, 2023.
Max materiality 0.90 · Median 0.65 · Most common event other_material